The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Tofacitinib Promising for Psoriatic Arthritis & FDA Issues Alert for Warning for Saxagliptin & Alogliptin Diabetes Treatments

Tofacitinib Promising for Psoriatic Arthritis & FDA Issues Alert for Warning for Saxagliptin & Alogliptin Diabetes Treatments

May 4, 2016 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270Tofacitinib Has Positive Results in Phase 3 for Psoriatic Arthritis
The OPAL (Oral Psoriatic Arthritis triaL) Broaden study is a Phase 3 clinical trial evaluating tofacitinib for treating psoriatic arthritis.1 This study evaluated the safety and efficacy of 5 mg tofacitinib and 10 mg tofacitinib twice daily in adults with active psoriatic arthritis who had an inadequate response to at least one conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) and who had not yet tried a tumor necrosis factor inhibitor (TNFi-naive).

You Might Also Like
  • FDA Issues Warning for Joint Pain from Diabetes Drugs
  • FDA Committee Recommends Tofacitinib Approval
  • FDA Issues Boxed Warning for Hydroxyurea & Neutropenia May Occur after Rituximab Treatments
Also By This Author
  • Apremilast Proves Effective for PsA with Skin Involvement

At Month 3, primary efficacy endpoint measures were demonstrated for both active dosing regimens and were superior to placebo. These endpoints included the ACR20 response and the Health Assessment Questionnaire Disability Index (HAQ-DI) score. The study evaluated improvement in physical functioning. During the study, patients were allowed to continue background csDMARDs at a stable dose. An active control arm in the study was 40 mg adalimumab administered subcutaneously every two weeks. Overall, 422 patients were randomized in a 2:2:2:1:1 ratio to one of the following treatment arms: 5 mg tofacitinib twice daily, 10 mg tofacitinib twice daily, 40 mg adalimumab every two weeks, placebo to 5 mg tofacitinib twice daily, and placebo to 10 mg tofacitinib twice daily.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

During this 12-month study, safety results were consistent with those previously described. All treatment groups had similar rates of treatment emergent adverse events, serious adverse events and adverse events leading to therapy discontinuation. Observed serious adverse events were consistent with events seen in other tofacitinib clinical trials.

FDA Updates Warning for Saxagliptin & Alogliptin Diabetes Medications
Following a safety review, the U.S. Food and Drug Administration (FDA) has updated the Feb. 11, 2014, Drug Safety Communication related to an increased risk of heart failure, particularly in patients who already have heart or kidney disease, in individuals taking saxagliptin and alogliptin.2 New warnings are, therefore, being added to the drugs’ labels.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The FDA evaluated two large clinical trials conducted in patients with heart disease that showed that more patients who received medicines containing saxagliptin or alogliptin were hospitalized for heart failure compared with patients who received placebo. Saxagliptin-treated patients had a 3.5% heart failure hospitalization rate compared with 2.8% of placebo-treated patients. This finding equates to 35 of every 1,000 patients vs. 28 of every 1,000 patients. Alogliptin-treated patients had a 3.9% heart failure hospitalization rate compared with 3.3% of placebo-treated patients, which equates to 39 of every 1,000 patients vs. 33 of every 1,000 patients.

Healthcare professionals who identify patients who develop heart failure symptoms while taking alogliptin or saxagliptin should consider discontinuing these medications and seek other medications for glucose control.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to medication use to FDA’s MedWatch Adverse Event Reporting Program.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Pfizer Inc. News release: Pfizer announces positive top-line results from the first phase 3 trial of investigational tofacitinib in adults with psoriatic arthritis. 2016 Apr 5.
  2. U.S. Food and Drug Administration. Safety alert: Diabetes medications containing aaxagliptin and slogliptin: drug safety communication—risk of heart failure. 2016 Apr 5.

Pages: 1 2 | Multi-Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: adalimumab, alogliptin, diabetes, FDA, Food and Drug Administration, Psoriatic Arthritis, saxagliptin, Tofacitinib

You Might Also Like:
  • FDA Issues Warning for Joint Pain from Diabetes Drugs
  • FDA Committee Recommends Tofacitinib Approval
  • FDA Issues Boxed Warning for Hydroxyurea & Neutropenia May Occur after Rituximab Treatments
  • FDA Issues Stronger Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Warning

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)